

**Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Name of the Target Company (TC)	Pfizer Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Pfizer Corporation (as seller)		
Whether the acquirer belongs to Promoter/Promoter group	Yes. Post acquisition.		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	The National Stock Exchange of India Limited and the BSE Limited		
Details of the acquisition / disposal as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable (*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
<b>Before the acquisition/disposal under consideration, holding of :</b>			
a) Shares carrying voting rights	9,376,100	31.42%	31.42%
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	Nil	Nil	Nil
c) Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
<b>e) Total (a+b+c+d)</b>	<b>9,376,100</b>	<b>31.42%</b>	<b>31.42%</b>
<b>Details of acquisition/sale</b>			
a) Shares carrying voting rights acquired/sold	9,376,100	31.42%	31.42%
b) VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the	Nil	Nil	Nil

TC (specify holding in each category) acquired/sold			
d) Shares encumbered / invoked/released by the acquirer.	Nil	Nil	Nil
<b>e) Total (a+b+c+/-d)</b>	9,376,100	31.42%	31.42%
<b>After the acquisition/sale, holding of:</b>			
a) Shares carrying voting rights	Nil	Nil	Nil
b) Shares encumbered with the acquirer	Nil	Nil	Nil
c) VRs otherwise than by equity shares	Nil	Nil	Nil
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
<b>e) Total (a+b+c+d)</b>	Nil	Nil	Nil
Mode of <del>acquisition/sale</del> (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	inter-se transfer (off market)		
Date of <del>acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares</del> , whichever is applicable	<b>MARCH 03, 2014</b>		
Equity share capital / total voting capital of the TC before the said acquisition/sale	29,841,440 shares		
Equity share capital/ total voting capital of the TC after the said acquisition/sale	29,841,440 shares		
Total diluted share/voting capital of the TC after the said acquisition/sale	29,841,440 shares		

**Note:**

(\*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**Signature of the acquirer / seller / Authorised Signatory**

**Pfizer Corporation**



**Place: New York, New York USA**

**Date: MARCH 04, 2014**